Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmacorp Rx Inc. ( (TSE:PCRX) ) has issued an update.
PharmaCorp Rx Inc. has granted 501,088 stock options to its directors, officers, employees and consultants, with an exercise price of $0.46 per common share and an expiry date of December 31, 2035, subject to TSX Venture Exchange approval. The company used exemptions under Multilateral Instrument 61-101 to proceed without a formal valuation or minority shareholder approval, noting that its shares are listed only on the TSX Venture Exchange and that the fair market value of the option grants to insiders does not exceed 25% of its market capitalization, underscoring a standard incentive move that aligns management and staff with long-term shareholder interests while navigating Canadian securities rules for related-party transactions.
More about Pharmacorp Rx Inc.
PharmaCorp Rx Inc. is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession planning for retiring pharmacy owners. Leveraging capital, strategic support and operational expertise, the company is building a national network of community pharmacies under the PharmaChoice Canada banner, currently operating seven locations and pursuing further acquisitions and rebranding of independent pharmacies across Canada. PharmaCorp’s shares trade on the TSX Venture Exchange under the symbol PCRX.
Average Trading Volume: 151,640
Technical Sentiment Signal: Hold
Current Market Cap: C$78.64M
See more data about PCRX stock on TipRanks’ Stock Analysis page.